Journey Medical Corporation Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 19 Fair Values set on narratives written by author
DERM Community Narratives
Rising Global Dermatologic Demand Will Fuel Future Success
Rosacea Market Tailwinds And Payer Access Will Drive Durable Long Term Dermatology Upside
Slow Reimbursement And Competitive Pressures Will Challenge Dermatology Prescriptions Yet Support Gradual Improvement
Slow Reimbursement And Competitive Pressures Will Challenge Dermatology Prescriptions Yet Support Gradual Improvement
View narrativeRising Global Dermatologic Demand Will Fuel Future Success
View narrativeRosacea Market Tailwinds And Payer Access Will Drive Durable Long Term Dermatology Upside
View narrativeTrending Discussion
No trending discussion available.
Recently Updated Narratives
DERM: Positive Operating Profit Will Support Ongoing Prescription And Pricing Momentum
DERM: Expanded Access And Parent Cash Backing Will Support Future Value
Rosacea Market Tailwinds And Payer Access Will Drive Durable Long Term Dermatology Upside
Snowflake Analysis
Journey Medical Corporation Key Details
- -0.22
- 65.45%
- -8.95%
- 79.3%
About DERM
- Founded
- 2014
- Employees
- 58
- CEO
- Website
View website
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.